Compound Profile
CJC 1295
GHRH analog peptide
CJC 1295 is a synthetic growth hormone releasing hormone (GHRH) analog engineered for a longer half life than natural GHRH, commonly combined with Ipamorelin in gray market protocols; its GH/IGF 1 mechanism has early pharmaceutical development data behind it, but no FDA approval and an uncertain compounding pathway.
Last reviewed:
C PreliminaryMonograph visual
CJC 1295
Generated profile category visual
Where to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Unapproved compound: FDA compounding status uncertain
CJC-1295 is not FDA-approved for any human use. It was removed from the FDA’s Category 2 restricted 503A bulk substances list in April 2026 following withdrawal of its nomination, but was not moved to the approved Category 1 list and is not on the July 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) review agenda.
- Research-use-only (RUO) product is not legally intended for human consumption.
- No long-term human safety or efficacy data exists for any dose or protocol.
- This profile is not a self-treatment guide.
Regulatory status
2026 federal and state regulatory context
Sellable only as research use only (RUO) product; compounding pharmacy pathway is uncertain and not scheduled for near term PCAC review.
Regulatory changelog
- 2023 04/2026: FDA Category 2 restricted (503A bulk substances). 2026 04: Removed from Category 2 following nomination withdrawal (gray zone, not Category 1). Not included on the July 23 24, 2026 PCAC review agenda (which covers BPC 157, KPV, TB 500, MOTS C, Emideltide/DSIP, Semax, and Epitalon).
Quick Stats
Evidence level
Preliminary evidence
Typical onset
Varies by prep
Safety rating
Use extra caution: Safety review pending
Best for
GHRH Receptor Agonism, DAC Albumin Binding Half Life Extension, Downstream IGF 1 Elevation
Avoid / review if
Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight
Safety & Cautions
Review before use if any apply: Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight.
Evidence-based safety
Caution when combined
These pairings share a flagged risk mechanism. They are additive-effect cautions derived from contraindication data, not confirmed clinical interactions. Consult a clinician before combining.
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Browse the grouped cautions below. The list scrolls inside this card when long.
- Acarbose
- ajoene
- Allicin
- Aloe Vera
- Alpha-Lipoic Acid
- American Ginseng Extract
- Andrographis
- Anemarrhena Asphodeloides
- Tarragon
- Ashoka
- Astragalus
- Astragalus Membranaceus
- Bael
- Berberis
- Berberis Vulgaris
- Black Seed
- Blueberry
- Buckwheat
- Burdock
- Caraway
- Cichorium Intybus
- Cinnamon
- Cinnamon extract
- Cissus
- Cistanche
- Cistanche Deserticola
- Citrus Bergamia
- Citrus Sinensis
- Coenzyme Q10
- Commiphora Mukul
- Coptis
- Coptis Chinensis
- Coriandrum Sativum
- Cornus Officinalis
- Curry Leaf
- D-Mannose
- D-Ribose
- Damiana
- Dandelion
- Dendrobium
- Devils Claw Extract
- Elderberry
- Elecampane
- Eucommia
- Fenugreek
- Fenugreek Extract
- Fingerroot
- Fisetin
- Fucoxanthin
- Garcinia Indica
- Garlic Extract
- Ginkgo Biloba Extract
- Panax Red Ginseng
- Panax White Ginseng
- Glucosamine
- Goldenseal
- Gudmar
- Gymnema
- Holy Basil / Tulsi (Ocimum tenuiflorum)
- Holy Basil Purple
- Holy Basil Seed
- Ipamorelin
- Jujube
- Kuding Tea
- Kudzu
- Banaba
- Luo Han Guo
- Mangifera Indica
- Marshmallow
- MCT Oil
- Bitter Melon
- Morinda Citrifolia
- Moringa
- Morus Alba
- Mulberry Leaf
- Myrtle
- Neem
- Nelumbo Nucifera
- Nettle Root
- Nigella Sativa
- Nicotinamide Mononucleotide
- Notoginseng
- Ocimum Basilicum
- Olive Leaf Extract
- Oregano
- Panax Ginseng Extract
- American Ginseng
- Papaya Leaf
- Phellodendron
- Phellodendron Amurense
- Psyllium
- Pueraria Lobata
- Pycnogenol
- Rehmannia Glutinosa
- Rehmannia Prepared
- Rice Bran
- Rooibos
- Roselle Seed
- Sage
- Salacia
- Semaglutide
- Serenoa Repens
- Shatavari
- Soursop
- Tamarind
- Tirzepatide
- Tongkat Ali
- Fenugreek
- Wild Yam
- Ashwagandha
Evidence Summary
C PreliminaryEvidence lens
Early signal that needs stronger human replication before practical claims.
Human clinical evidence: Not the primary signal
Mechanistic / preclinical: Mechanism mapped — GHRH Receptor Agonism · DAC Albumin Binding Half Life Extension · Downstream IGF 1 Elevation
Research maturity: Preliminary or mixed — main contexts: GHRH Receptor Agonism · DAC Albumin Binding Half Life Extension · Downstream IGF 1 Elevation
Safety boundary: Safety note available — Review before use if any apply: Pregnancy/Breastfeeding, Uncontrolled Diabetes, Unsupervised RUO Product Use Without Physician Oversight.
Confidence estimate based on the design quality and consistency of published clinical trials.
CJC 1295 has a preliminary evidence evidence rating.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
How CJC 1295 Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How CJC 1295 Works
Mechanisms & Biological Pathways▼
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the CJC 1295 evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
⚠️ Sourcing Options Disabled for Safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions below under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Compound profile context
How to interpret CJC 1295
CJC 1295 dosage by use case, onset and duration, safety limits, and interactions for ghrh receptor agonism, graded against research. Mechanistic Evidence… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing CJC 1295, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.